Most Important GLP-1 Studies 2023–2026: The Evidence Behind Ozempic, Wegovy, Mounjaro, Zepbound and the Next Generation
Updated: September 2026 GLP-1 medicines have moved from being primarily diabetes treatments to becoming a major platform for obesity and cardiometabolic medicine. The strongest clinical-trial evidence now extends beyond weight loss to cardiovascular disease, chronic kidney disease, heart failure, metabolic liver disease and other obesity-related complications. But "GLP-1" is not one drug, and the studies are not interchangeable. Semaglutide, tirzepatide, liraglutide and newer investigational medicines act on overlapping but different metabolic pathways, and the populations, doses and outcomes studied vary substantially. Key takeaway: The most important GLP-1 evidence through 2026 falls into several categories: weight loss, cardiovascular outcomes, kidney outcomes, heart failure, metabolic liver disease, diabetes control, long-term weight maintenance and next-generation multi-receptor drugs. The strongest conclusions come from randomized controlled trials with c...